Last update 01 Nov 2024

Cough variant asthma

Last update 01 Nov 2024

Basic Info

Synonyms

Cough variant asthma, Cough variant asthma (disorder), asthma cough variant

+ [4]

Introduction

Asthma which is characterized by CHRONIC COUGH that is nonproductive without other asthmatic symptoms, e.g., WHEEZING, and PAROXYSMAL DYSPNEA. Cough-variant asthma is accompanied by AIRWAY HYPERSENSITIVITY and may progress to classical asthma without treatment.

Drugs associated with Cough variant asthma

SuHuangZhiKe

Target-

Mechanism-

Active Org.

Jiangsu Yangtze River Pharmaceutical Group Co., Ltd. [+1]

Originator Org.

Jiangsu Yangtze River Pharmaceutical Group Co., Ltd.

Active Indication

Common Cold [+2]

Inactive Indication-

Drug Highest PhaseApproved

First Approval Ctry. / Loc.

First Approval Date04 Feb 2008

Maqin Granules

Target-

Mechanism-

Active Org.

Sichuan Academy of Chinese Medicine Sciences

Originator Org.

Sichuan Academy of Chinese Medicine Sciences

Active Indication

Common Cold [+2]

Inactive Indication-

Drug Highest PhasePhase 2

First Approval Ctry. / Loc.-

First Approval Date20 Jan 1800

Shufeng Zhike Granules

Target-

Mechanism-

Active Org.

Beijing Zhongyan Tongrentang Pharmaceutical R&D Co., Ltd.

Originator Org.

Beijing Zhongyan Tongrentang Pharmaceutical R&D Co., Ltd.

Active Indication

Cough variant asthma

Inactive Indication-

Drug Highest PhasePhase 2

First Approval Ctry. / Loc.-

First Approval Date20 Jan 1800

Clinical Trials associated with Cough variant asthma

NCT06590740 / Not yet recruitingNot Applicable

Establishment of a FeNO Cutoff Value for Evaluating the Response to Budesonide-formoterol in Patients With Chronic Cough Suggestive of Cough Variant Asthma: a Multicenter Prospective Clinical Study

This is a multicenter, prospective, single-arm, interventional clinical study to predict the response to budesonide-formoterol treatment in patients with chronic dry or nocturnal cough by determining a cut off value of FeNO. In this study, the response to ICS/LABA treatment is defined as reduction in cough VAS score from baseline of ≥30 mm after 8 weeks of ICS/LABA treatment. Subjects will be treated with Symbicort® 160/4.5 mcg, 1 puff, BID for 8 weeks with 4 study visits: Visit 1 (Day 0), Visit 2 (week 4) and Visit 3, end of study (week 8) and Visit 4, 4 weeks after treatment discontinuation, (week 12). Baseline data will be collected at Day-5 to Day0.
This study will be conducted at around 40 study sites in China. Approximately 1000 patients (age ≥18 years old) with dry cough or nocturnal cough symptoms for at least 8 weeks and no other obvious cause for their cough will be enrolled into this study.

Start Date30 Dec 2024

Sponsor / Collaborator

AstraZeneca PLC

ChiCTR2400083289 / RecruitingPhase 4IIT

Clinical study on the treatment of cough variant asthma with Jingfang Keli

Start Date22 Apr 2024

Sponsor / Collaborator

Zhujiang Hospital of Southern Medical University

ChiCTR2400086509 / RecruitingEarly Phase 1IIT

A multicenter randomized controlled clinical study on the treatment of cough variant asthma (phlegm heat accumulation in the lungs) in children with pediatric cough granules

Start Date13 Apr 2024

Sponsor / Collaborator-

100 Clinical Results associated with Cough variant asthma

100 Translational Medicine associated with Cough variant asthma

0 Patents (Medical) associated with Cough variant asthma

387

Literatures (Medical) associated with Cough variant asthma

01 Dec 2024·Radiology Case Reports

Post-traumatic pulmonary embolism in the setting of cough-variant asthma

Article

Author: Mudassar, Muhammad ; Saleem, Aeman ; Usman, Aleena ; Saleem, Muhammad Muaz

Post-traumatic pulmonary embolism (PE) poses diagnostic complexities, especially with underlying lung pathologies and delayed symptoms. We report a 43-year-old male who presented with cough, frothy sputum, and dyspnea following blunt chest trauma 2 weeks ago. Due to a history of asthma, an asthma exacerbation was suspected but he failed to respond to bronchodilator therapy. Doppler USG (ultrasonography) was negative for deep venous thrombi, however, elevated D-dimer levels prompted further investigation with computed tomography pulmonary angiography (CTPA), confirming the diagnosis of PE. Prompt initiation of anticoagulation and thrombolysis resulted in clinical improvement. This case underscores the need to rule out posttraumatic PE, irrespective of age, type of, or time since injury, and underlying lung disease, to ensure timely diagnosis and intervention.

01 Sep 2024·Journal of Thoracic Disease

Bronchial asthma with normal forced expiratory volume in 1 second (FEV1) compared with low FEV1

Article

Author: Ohwada, Akihiko ; Kitaoka, Hiroko

BackgroundCough variant asthma (CVA) is characterized by cough as a sole symptom and normal pulmonary function. However, it is unclear whether CVA really common among asthmatic patients with normal forced expiratory volume in 1 second (FEV1). The aim of this study was to evaluate the incidence of cough alone symptom among the subjects with normal FEV1 and to evaluate their differences from ordinary asthmatic subjects.MethodsWe defined normal FEV1 as ≥90% predicted based on the article of Kotti GH. Of the patients with normal FEV1, we chose subjects without wheeze, and the duration of cough was not to ask, since the symptoms often occurred with acute exacerbation and timing of visiting a doctor depended on each patient's perception. Test for airway hyperresponsiveness was not performed in this study. Visual analogue scale (VAS) scores for cough and dyspnea, FEV1, and fractional exhaled nitric oxide (FeNO) responsiveness to inhaled corticosteroid (ICS)/long-acting beta2 agonist (LABA) treatment were compared in patients with normal FEV1 and with low FEV1 <90%. Correlations of changes in symptoms with changes of FEV1, FeNO, peripheral eosinophil count, and serum immunoglobulin E (IgE) at single time point were also examined in each group and in overall patients.ResultsThe participants were 329 physician-diagnosed treatment-naive patients with asthma who were divided into 187 in normal FEV1 and 142 in low FEV1 groups. Cough without dyspnea was present in 16 patients (8.6%) in the normal FEV1 group, suggesting candidates for CVA in this analysis were quite few. Improvement in symptoms after treatment was similar between both groups. But VAS scores of dyspnea were still higher in the low FEV1 group. The degree of improvement in FEV1 after ICS/LABA treatment was less in the normal FEV1 group than in the low FEV1 group, but was still evident. Peripheral eosinophil count, serum IgE, and FeNO values before treatment were lower in the normal FEV1 group. In overall patients, improvements of symptoms after treatment were significantly correlated with FEV1 changes. Improvement of dyspnea was also significantly related to peripheral eosinophil count and change of FeNO, whereas improvement of cough was not related to these T helper 2 (Th2) response markers.ConclusionsCandidates for CVA among the patients with asthma with predicted FEV1 ≥90% were few. Participants with normal FEV1 respond well to ICS/LABA treatment for improvement of symptom. The change of FEV1 after treatment, and the pre-treatment blood eosinophil count, serum IgE, and FeNO were lower in normal FEV1 cases than in low FEV1 cases. These observations suggest asthmatic patients with normal FEV1, including candidates for CVA having just common mild asthma. In overall participants, symptoms of cough and dyspnea were similar, but were not identical in relation to the Th2 background.

01 Sep 2024·Heliyon

Small airway inflammation in atypical asthma

Article

Author: Han, Junjie ; Song, Yuanlin ; Shi, Lin ; Chen, Cuicui ; She, Jun ; Gong, Ying ; Wang, Jian ; Song, Juan ; Li, Li ; Zhu, Yichun

BackgroundLess attention has been paid to the pathophysiological changes in atypical asthma such as cough variant asthma (CVA) and chest tightness variant asthma (CTVA). The obstruction of large and small airways is the important component in the development of asthma. We investigated whether small airway inflammation (SAI) induced small airway dysfunction (SAD) in these atypical asthmatics.MethodsSix hundred and eighty-six patients were enrolled and analyzed in the study. The partitioned airway inflammation was assessed by fractional exhaled nitric oxide (FeNO), such as FnNO, FeNO₅₀, FeNO₂₀₀, and calculated alveolar fraction of exhaled NO (CaNO_dual). Correlations between exhaled NOs and SAD-related variables were assessed, whereas cell classification was evaluated by Spearman's rank tests. Classic asthma, CVA, and CTVA about potential risk were conducted using binary logistic regression models.ResultsThe whole airway inflammation increased in classic and atypical asthma than controls, whereas the central and peripheral airway inflammation in the CVA and CTVA groups increased compared with the classic asthma group. Smoking exposure was found to increase the central and peripheral airway inflammation in patients with asthma. The exhaled NO of FeNO₅₀ and FeNO₂₀₀ was associated with SAD in classic asthma, but not in CVA and CTVA. FeNO₂₀₀ was the main risk (adjusted odds ratio [OR], 1.591; 95 % CI, 1.121-2.259; P = .009) in classic asthma and (adjusted OR, 1.456; 95 % CI, 1.247-1.700; P = .000) in CVA. The blood eosinophil levels were correlated with FeNO₅₀ and FeNO₂₀₀ in classic asthma and atypical asthma.ConclusionMore severe inflammatory process was present in central and peripheral airways in CVA and CTVA, which might reflect a pre-asthmatic state. SAI was the predominant risk factor in the development of asthma before SAD.

Analysis

Perform a panoramic analysis of this field.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Cough variant asthma

Basic Info

Related

Analysis